CONSTILAC Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Constilac, and what generic alternatives are available?
Constilac is a drug marketed by Alra and is included in one NDA.
The generic ingredient in CONSTILAC is lactulose. There are twenty drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the lactulose profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Constilac
A generic version of CONSTILAC was approved as lactulose by PHARM ASSOC on July 30th, 1996.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for CONSTILAC?
- What are the global sales for CONSTILAC?
- What is Average Wholesale Price for CONSTILAC?
Summary for CONSTILAC
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 28 |
| Clinical Trials: | 1 |
| Patent Applications: | 3,588 |
| DailyMed Link: | CONSTILAC at DailyMed |
Recent Clinical Trials for CONSTILAC
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Tampa General Hospital | Phase 4 |
US Patents and Regulatory Information for CONSTILAC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alra | CONSTILAC | lactulose | SOLUTION;ORAL | 071054-001 | Jul 26, 1988 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
